Alastair Smith, chief executive of (), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year.
Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.
Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE